Contineum Therapeutics Appoints New CMO and CSO
Ticker: CTNM · Form: 8-K · Filed: May 31, 2024 · CIK: 1855175
| Field | Detail |
|---|---|
| Company | Contineum Therapeutics, Inc. (CTNM) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Contineum swapped CMOs and brought in a new CSO. Big moves in R&D leadership.
AI Summary
Contineum Therapeutics, Inc. announced on May 24, 2024, the appointment of Dr. Jonathan Leipsic as Chief Medical Officer and Dr. David E. Johnson as Chief Scientific Officer. The company also reported the departure of Dr. David M. Epstein from his role as Chief Medical Officer. These changes are effective immediately.
Why It Matters
Key leadership changes in medical and scientific roles can signal shifts in the company's strategic direction and research priorities.
Risk Assessment
Risk Level: medium — Changes in key scientific and medical leadership can introduce uncertainty regarding future research and development strategies.
Key Players & Entities
- Contineum Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan Leipsic (person) — Appointed Chief Medical Officer
- Dr. David E. Johnson (person) — Appointed Chief Scientific Officer
- Dr. David M. Epstein (person) — Departed Chief Medical Officer
- May 24, 2024 (date) — Effective date of changes
FAQ
Who has been appointed as the new Chief Medical Officer at Contineum Therapeutics?
Dr. Jonathan Leipsic has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer at Contineum Therapeutics?
Dr. David E. Johnson has been appointed as the new Chief Scientific Officer.
Who has departed from their role as Chief Medical Officer?
Dr. David M. Epstein has departed from his role as Chief Medical Officer.
What is the effective date of these leadership changes?
The changes are effective as of May 24, 2024.
What was Contineum Therapeutics' former company name?
Contineum Therapeutics, Inc.'s former company name was Pipeline Therapeutics, Inc.
Filing Stats: 1,219 words · 5 min read · ~4 pages · Grade level 14.4 · Accepted 2024-05-31 17:10:26
Key Financial Figures
- $0.001 — tered Class A Common Stock , par value $0.001 per share CTNM The Nasdaq Global Mar
Filing Documents
- cont20240524_8k.htm (8-K) — 39KB
- ex_681655.htm (EX-10.1) — 83KB
- ex_681656.htm (EX-10.2) — 22KB
- 0001437749-24-018934.txt ( ) — 304KB
- noticker-20240524.xsd (EX-101.SCH) — 3KB
- noticker-20240524_def.xml (EX-101.DEF) — 12KB
- noticker-20240524_lab.xml (EX-101.LAB) — 15KB
- noticker-20240524_pre.xml (EX-101.PRE) — 12KB
- cont20240524_8k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Contineum Therapeutics, Inc. Executive Severance Plan. 10.2 Form of Registrant's Mutual Arbitration Agreement. 104 Cover Page Interactive Data File (embedded within XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 31, 2024 Contineum Therapeutics, Inc. By: /s/ Peter Slover Peter Slover Chief Financial Officer Principal Financial Officer and Principal Accounting Officer